Cover Image
市場調查報告書

子宮內膜異位症治療藥的全球市場:2016-2020年

Global Endometriosis Drugs Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 363164
出版日期 內容資訊 英文 70 Pages
訂單完成後即時交付
價格
Back to Top
子宮內膜異位症治療藥的全球市場:2016-2020年 Global Endometriosis Drugs Market 2016-2020
出版日期: 2016年07月08日 內容資訊: 英文 70 Pages
簡介

子宮內膜異位症是女性特有的健康障礙,子宮內腔的膜組織在子宮腔外側增殖,該子宮內膜組織在月經期間流出體外。在子宮腔外側增殖的組織稱為子宮內植入物。還有子宮內膜異位症也發生在輸卵管和卵巢,骨盆腔,陰道,子宮頸部,子宮囊。還有也有稀少的在肺和腦,皮膚等身體各部分發生的病例報告。大抵的情況,植入物是無害性質,不過,可說是生育年齡女性受到許多影響的疾病。子宮內膜異位症治療藥的全球市場,預計今後數年的年複合成長率為2.05%。

本報告以子宮內膜異位症治療藥的全球市場為焦點,提供2016-2020年期間其變遷的各治療形式,總資產利益及地區(南北美洲,歐洲、中東、非洲,亞太地區)的分析、預測,未來的發展樣貌,預測,主要加入企業簡介等的最新資訊彙整。

第1章 摘要整理

  • 焦點

第2章 報告的範圍

  • 市場概要
  • 主要供給企業的銷售產品

第3章 市場調查方法

  • 取材方式
  • 經濟指標

第4章 簡介

  • 主要市場焦點
  • 子宮內膜異位症 - 概要

第5章 開發平台分析

  • 以自我機制為基礎的開發平台分子

第6章 重要購買標準

第7章 市場環境

  • 市場概要
  • 波特的五力分析

第8章 子宮內膜異位症治療藥的全球市場:各治療形式

  • 荷爾蒙治療
  • 市場規模與預測
  • 止痛藥給藥
  • 市場規模與預測

第9章 子宮內膜異位症治療藥的全球市場:各給藥途徑

  • 口服給藥
  • 非口服給藥
  • 子宮內系統
  • 鼻腔用噴霧

第10章 子宮內膜異位症治療藥的全球市場:各地區

  • 子宮內膜異位症治療藥的全球市場 - 各地區:2015-2020年
  • 南北美洲的子宮內膜異位症治療藥市場
  • 歐洲、中東、非洲的子宮內膜異位症治療藥市場
  • 亞太地區的子宮內膜異位症治療藥市場

第11章 子宮內膜異位症治療藥的全球市場:推動要素

  • 子宮內膜異位症的復發性
  • 口服避孕藥的普及
  • 從非有效率的現有療法帶來的廣泛未滿足需求

第12章 推動要素的影響度

第13章 子宮內膜異位症治療藥的全球市場:課題

  • 導致治療中斷的低遵守率
  • 作為一次治療選項的外科手術
  • 缺少適當的診斷工具

第14章 推動要素及課題的影響度

第15章 子宮內膜異位症治療藥的全球市場:趨勢

  • GnRH拮抗劑替換GnRH受體激動劑
  • 對子宮內避孕用具的關注度高漲
  • 開發新的治療目標

第16章 商業環境

  • 競爭情形
  • 重要新聞
  • 下一代的主要供給企業

第17章 主要供給企業分析

  • AbbVie
  • AstraZeneca
  • Bayer HealthCare
  • Pfizer
  • 其他主要企業

第18章 附錄

  • 簡稱一覽

第19章 關於Technavio

目錄
Product Code: IRTNTR9808

About the Endometriosis Market

Endometriosis is a common health condition in women where the endometrial tissue, which is found in the lining of the uterus, appears and grows outside the uterine cavity. The endometrial tissue is shed from the body during menstruation.

The tissue growing outside the uterine cavity is called endometrial implants. Endometriosis can also occur in the fallopian tubes, ovaries, pelvic cavity, vagina, cervix, and bladder. In rare cases, it has been reported in other parts of the body such as the lungs, brain, and skin. These implants are usually benign in nature. Women of reproductive age are often affected by this condition.

Endometriosis often occurs due to retrograde menstruation, where the menstrual blood flows back into the pelvic cavity instead of leaving the body. This then adheres to the surface of the bladder, ovaries, or rectum and continues to grow or thicken over the course of each menstrual cycle.

Technavio's analysts forecast the global endometriosis market to grow at a CAGR of 2.05% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global endometriosis market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of approved and off-label branded and generic drugs used for the treatment and prevention of endometriosis and related pain. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Endometriosis Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AbbVie
  • AstraZeneca
  • Bayer HealthCare
  • Pfizer

Other Prominent Vendors

  • Addex Therapeutics
  • Astellas Pharma
  • Debiopharm
  • ElexoPharm
  • Endoceutics
  • Euroscreen
  • Forendo Pharma
  • Isifer
  • Kissei Pharmaceutical
  • Neurocrine Biosciences
  • Nippon Shinyaku
  • ObsEva
  • Orphagen Pharmaceuticals
  • Philogen
  • PregLem
  • Repros Therapeutics
  • Roivant Sciences
  • SK Chemicals
  • Speciality European Pharma
  • SYNG Pharmaceuticals
  • Takeda
  • United Pharmaceuticals
  • ValiPharma

Market driver

  • Increased adoption of OCPs
  • For a full, detailed list, view our report

Market challenge

  • Surgeries as primary treatment option
  • For a full, detailed list, view our report

Market trend

  • Increased focus on intrauterine devices (IUDs)
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights
  • Endometriosis: An overview

PART 05: Pipeline analysis

  • Pipeline molecules based on their mechanism

PART 06: Key buying criteria for endometriosis drugs

PART 07: Market landscape

  • Market overview
  • Five forces analysis

PART 08: Market segmentation by type of therapy

  • Hormone therapy
  • Market size and forecast
  • Pain medications
  • Market size and forecast

PART 09: Market segmentation by ROA

  • Oral
  • Parenteral
  • Intrauterine systems
  • Nasal spray

PART 10: Geographical segmentation

  • Global endometriosis drugs market by geography 2015-2020
  • Endometriosis drugs market in Americas
  • Endometriosis drugs market in EMEA
  • Endometriosis drugs market in APAC

PART 11: Market drivers

  • Recurrence of endometriosis
  • Increased adoption on OCPs
  • Ineffective existing therapies leading to high unmet need

PART 12: Impact of drivers

PART 13: Market challenges

  • Poor compliance rates leading to high dropouts
  • Surgeries as primary treatment option
  • Unavailability of proper diagnostic tools

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Replacement of GnRH agonists by GnRH antagonists
  • Increased focus on IUDs
  • Development of novel targets for treatment

PART 16: Vendor landscape

  • Competitive scenario
  • Key news
  • Major upcoming vendors

PART 17: Key vendor analysis

  • AbbVie
  • AstraZeneca
  • Bayer HealthCare
  • Pfizer
  • Other prominent vendors

PART 18: Appendix

  • List of abbreviations

PART 19: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Pipeline portfolio: Global endometriosis drugs market
  • Exhibit 03: Segmentation of pipeline molecules in different stages of development
  • Exhibit 04: Segmentation of pipeline molecules based on their mechanism of action
  • Exhibit 05: Impact of GnRH antagonists on global endometriosis market
  • Exhibit 06: Competitive assessment of marketed and late-stage pipeline molecules
  • Exhibit 07: Key buying criteria for endometriosis drugs
  • Exhibit 08: Global endometriosis market snapshot: Developed and emerging markets 2015
  • Exhibit 09: Global endometriosis drugs market 2015-2020 ($ billions)
  • Exhibit 10: Opportunity analysis: Global endometriosis drugs market
  • Exhibit 11: Five forces analysis
  • Exhibit 12: Segmentation of global endometriosis drugs market by type of therapy
  • Exhibit 13: Global endometriosis market segmentation by type of therapy 2015
  • Exhibit 14: Hormone therapies market for endometriosis 2015-2020 ($ billions)
  • Exhibit 15: Pain medications market for endometriosis 2015-2020 ($ millions)
  • Exhibit 16: Global endometriosis market by type of therapy 2015-2020
  • Exhibit 17: Global endometriosis drugs market by geography 2015-2020
  • Exhibit 18: Segmentation of global endometriosis drugs market by geography 2015 and 2020
  • Exhibit 19: Segmentation of global endometriosis drugs market by geography 2015-2020 ($ millions)
  • Exhibit 20: Global endometriosis market by geography 2015-2020
  • Exhibit 21: Endometriosis drugs market in Americas 2015-2020 ($ millions)
  • Exhibit 22: Endometriosis prevalence in EMEA
  • Exhibit 23: Endometriosis drugs market in EMEA 2015-2020 ($ millions)
  • Exhibit 24: Endometriosis drugs market in APAC 2015-2020 ($ millions)
  • Exhibit 25: Impact of drivers
  • Exhibit 26: Impact of drivers and challenges
  • Exhibit 27: Market share of top vendors in global endometriosis drugs market 2015
  • Exhibit 28: Geographical presence of major vendors in global endometriosis market
  • Exhibit 29: Competitive scenario of vendors in global endometriosis market 2015-2020
  • Exhibit 30: Major upcoming vendors in global endometriosis market
  • Exhibit 31: AbbVie: YoY revenue and growth rate of Lupron 2013-2015 ($ millions)
  • Exhibit 32: AbbVie: Geographical segmentation of Lupron by revenue 2015
  • Exhibit 33: AbbVie: Metrics analysis
  • Exhibit 34: AstraZeneca: YoY revenue and growth rate of Zoladex 2013-2015 ($ millions)
  • Exhibit 35: AstraZeneca: Geographic segmentation of Zoladex 2015
  • Exhibit 36: AstraZeneca: Metrics analysis
  • Exhibit 37: Bayer: YoY revenue and growth rate of Mirena 2013-2015 ($ billions)
  • Exhibit 38: Bayer HealthCare: Metrics analysis
  • Exhibit 39: Pfizer: YoY revenue and growth rate of Depo-Provera 2013-2015 ($ millions)
  • Exhibit 40: Pfizer: Metrics analysis
Back to Top